Beyond glycemic control: differential effects of empagliflozin and sitagliptin on insulin sensitivity and a shared increase in adropin in type 2 diabetes - PubMed
3 hours ago
- #Insulin Sensitivity
- #Empagliflozin
- #Adropin
- Empagliflozin and sitagliptin, both added to metformin, significantly increased serum adropin levels in patients with type 2 diabetes over 12 weeks.
- Empagliflozin showed a greater reduction in insulin resistance (HOMA-IR) and fasting insulin compared to sitagliptin.
- Empagliflozin provided superior improvements in HbA1c, triglycerides, and HDL-C versus sitagliptin.
- Both treatments reduced TNF-α levels and body weight/BMI similarly, indicating anti-inflammatory effects.
- The study concluded empagliflozin offers broader metabolic benefits, while the adropin increase may be a general treatment-responsive biomarker.